title: MFH of bone and osteosarcoma show similar survival and chemosensitivity.
abstract: BACKGROUND
  Patients with malignant fibrous histiocytoma of bone (MFH-B) and osteosarcoma reportedly have comparable survival rates, despite the lesser chemosensitivity of patients with MFH-B compared with those with osteosarcoma.
  
  
  OBJECTIVE
  We therefore asked (1) whether there is a difference in the initial tumor volume, histologic response, and survival between cohorts with MFH-B and osteosarcoma, and (2) whether histologic responses and survival rates differed between two groups even after matching for volume and age.
  
  
  METHODS
  We retrospectively compared 27 patients with Stage IIB MFH-B with 389 patients with localized osteosarcoma for initial tumor volume, age, histologic response, and survival. We compared histologic response and survival between 27 patients with MFH-B and 54 patients with osteosarcoma matched for tumor volume and age.
  
  
  RESULTS
  MFH-B occurred more frequently in older patients and they presented with a smaller mean tumor volume and more frequent osteolytic pattern when compared with patients with osteosarcoma. The 5-year metastasis-free survival rates of the MFH-B and osteosarcoma groups were similar: 61.2% ± 9.7% and 61.3% ± 2.5%, respectively. We observed similar proportions of good responders to chemotherapy in the two groups, and the 5-year metastasis-free survival rates were 61.2% ± 9.7% and 70.4% ± 6.2%, respectively.
  
  
  CONCLUSIONS
  Patients with MFH-B and osteosarcoma have similar survival rates and histologic responses to chemotherapy. Although MFH-B and osteosarcoma differ in clinical presentation, their response pattern to contemporary therapy is similar.
  
  
  METHODS
  Level III, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.
authors.affiliation: Department of Orthopedic Surgery, Korea Cancer Center Hospital, 215-4, Gongneung-dong, Nowon-gu, Seoul 139-706, Korea. dgjeon@kcch.re.kr
authors.forename: Dae-Geun
authors.initials: DG
authors.lastname: Jeon
authors.forename: Won Seok
authors.initials: WS
authors.lastname: Song
authors.forename: Chang-Bae
authors.initials: CB
authors.lastname: Kong
authors.forename: Jung Ryul
authors.initials: JR
authors.lastname: Kim
authors.forename: Soo-Yong
authors.initials: SY
authors.lastname: Lee
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D051677:Histiocytoma, Malignant Fibrous / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012516:Osteosarcoma / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D011379:Prognosis; D056910:Republic of Korea / Q000453:epidemiology; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents